{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:41:52Z","timestamp":1780360912891,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3957,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"United States Public Health Service\u2014National Institutes of Health and the Dwoskin Family Foundation","award":["RO1 CA109335 and RO1 CA122105"],"award-info":[{"award-number":["RO1 CA109335 and RO1 CA122105"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1093\/annonc\/mdn629","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:24:01Z","timestamp":1223511841000},"page":"309-318","source":"Crossref","is-referenced-by-count":131,"title":["High incidence of false-positive PET scans in patients with aggressive non-Hodgkin\u2019s lymphoma treated with rituximab-containing regimens"],"prefix":"10.1016","volume":"20","author":[{"given":"H.S.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Escal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1093\/annonc\/mdn629_bb0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn629_bb0015","doi-asserted-by":"crossref","unstructured":"Lossos IS, Coleman F, Walker G, et al. Phase-2 study of R-MACLO-IVAM-T in newly diagnosed mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2007: 110.","DOI":"10.1182\/blood.V110.11.1363.1363"},{"issue":"4","key":"10.1093\/annonc\/mdn629_bb0020","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdn629_bb0025","first-page":"613","article-title":"Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma","volume":"85","author":"Jerusalem","year":"2000","journal-title":"Haematologica"},{"issue":"5\u20136","key":"10.1093\/annonc\/mdn629_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","article-title":"18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT","volume":"39","author":"Mikhaeel","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1093\/annonc\/mdn629_bb0035","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu","year":"2002","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1093\/annonc\/mdn629_bb0040","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdn629_bb0045","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdn629_bb0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1093\/annonc\/mdn629_bb0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-006-0151-z","article-title":"FDG-PET\/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease","volume":"85","author":"Querellou","year":"2006","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1093\/annonc\/mdn629_bb0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1093\/annonc\/mdn629_bb0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdn629_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1563-2571.2003.03003.x","article-title":"Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma","volume":"30","author":"Mikosch","year":"2003","journal-title":"Acta Med Austriaca"},{"issue":"5","key":"10.1093\/annonc\/mdn629_bb0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.bjc.6602040","article-title":"Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients","volume":"91","author":"Zinzani","year":"2004","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdn629_bb0080","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/annonc\/mdi271","article-title":"Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?","volume":"16","author":"Reinhardt","year":"2005","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdn629_bb0085","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdn629_bb0090","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00259-003-1120-6","article-title":"[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?","volume":"30","author":"Spaepen","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdn629_bb0095","doi-asserted-by":"crossref","unstructured":"Moskowitz C, Hamlin PA, Horwitz SM, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood (ASH Annual Meeting Abstracts) 2006: 108.","DOI":"10.1182\/blood.V108.11.532.532"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419404894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419404894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/2\/309\/393680\/mdn629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T12:29:55Z","timestamp":1582201795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419404894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0923753419404894"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn629","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}